Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Receives $54.50 Average Price Target from Analysts

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) have been assigned a consensus rating of “Moderate Buy” from the five research firms that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $54.50.

A number of research analysts have weighed in on the stock. D. Boral Capital reissued a “buy” rating and issued a $9.00 target price on shares of Citius Pharmaceuticals in a research note on Monday, June 9th. Maxim Group cut shares of Citius Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 23rd. Finally, Citigroup lowered shares of Citius Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 23rd.

Institutional Investors Weigh In On Citius Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Fisher Asset Management LLC purchased a new position in shares of Citius Pharmaceuticals during the 4th quarter worth $51,000. IFP Advisors Inc lifted its position in Citius Pharmaceuticals by 21.2% in the fourth quarter. IFP Advisors Inc now owns 40,416 shares of the company’s stock valued at $162,000 after buying an additional 7,083 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in Citius Pharmaceuticals by 103.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,212 shares of the company’s stock worth $33,000 after buying an additional 4,168 shares during the period. Hedge funds and other institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Trading Up 25.2%

NASDAQ:CTXR opened at $1.29 on Friday. The stock has a 50 day moving average of $0.85 and a two-hundred day moving average of $1.84. Citius Pharmaceuticals has a 12 month low of $0.65 and a 12 month high of $26.25.

Citius Pharmaceuticals (NASDAQ:CTXR) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.08) by ($0.19). On average, sell-side analysts expect that Citius Pharmaceuticals will post -4.5 earnings per share for the current fiscal year.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.